Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell TherapySylvain Lamure(Centre National de la Recherche Scientifique), Guillaume Cartron(Centre National de la Recherche Scientifique)CancersAugust 25, 202110.3390/cancers13174279Cited by 36SaveCiteExport RISWatch citationsRelated PapersFrom the bench to the bedside: ways to improve rituximab efficacy|Blood|2004|518